Shots:

• Twist to acquire Abveris for a total consideration of $190M including $150M at the closing of the transaction and $10M in cash, $40M at shares of Twist common stock

• The acquisition will complement & expand Twist’s biopharma Ab capabilities into mouse-based discovery and screening with the addition of Abveris’ in vivo Ab discovery platform for the development of therapies

• Abveris provides comprehensive Ab discovery and characterization services using its DiversimAb platform which can be humanized using the Twist antibody optimization solution to develop superior biologics for clinical advancement

Ref: Twist Bioscience| Image: Twist Bioscience